MedTrace Logo

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

NCT01592370 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2025-10-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.

Conditions

Interventions

BIOLOGICAL

Nivolumab

Administered by intravenous (IV) infusion

BIOLOGICAL

Ipilimumab

Administered by IV infusion

BIOLOGICAL

Lirilumab

Administered by IV infusion

BIOLOGICAL

Daratumumab

Administered by IV infusion

DRUG

Pomalidomide

Administered PO

DRUG

Dexamethasone

Administered PO and by IV infusion

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-02
Primary Completion
2020-09-25
Completion
2024-07-09
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • France
  • Greece
  • Italy
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01592370 on ClinicalTrials.gov